IP Group

News

X-ray of the hand in rheumatoid arthritis

Istesso backer sees silver lining in failed arthritis trial

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Madrigal builds in MASH with $4.4bn+ Ribo alliance

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks